Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

World News: . []

CAMBRIDGE Mass and CARLSBAD Calif Dec 06 2018 GLOBE NEWSWIRE) -- Nasdaq BIIB and Ionis Pharmaceuticals Inc Nasdaq IONS announced today that Biogen exercised its option to obtain from Ionis a worldwide exclusive, royalty-bearing license...

More news and information about Biogen Inc.; Ionis Pharmaceuticals, Inc.

Published By:

Globe Newswire: 12:30 GMT Thursday 6th December 2018

Published: .

Search for other references to "biogen" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us